Literature DB >> 25773877

Expressional STAT3/STAT5 Ratio is an Independent Prognostic Marker in Colon Carcinoma.

Fee Klupp1, Johannes Diers1, Christoph Kahlert1, Lena Neumann1, Niels Halama2, Clemens Franz1, Thomas Schmidt1, Felix Lasitschka3,4, Arne Warth3, Juergen Weitz5, Moritz Koch5, Martin Schneider6, Alexis Ulrich1.   

Abstract

BACKGROUND: Signal transducer and activator of transcription proteins (STATs) are crucial regulators of cell growth and differentiation; however, their specific prognostic impact in human colon cancer has only been studied to limited extent. We aimed to assess the prognostic significance of specific STAT expression patterns in colon carcinoma.
METHODS: Protein expression patterns of activated STAT1, STAT3, STAT4, and STAT5 in human colon carcinoma tissue and corresponding healthy mucosa (n = 104) were assessed using multiplex bead-based immunoassay technologies. Expression patterns were correlated with clinical and survival data. Immunohistochemistry was performed to assess spatial expression of STAT3 and STAT5.
RESULTS: STAT3 was underexpressed whereas STAT4 and STAT5 were overexpressed in colon carcinoma tissue. Primary tumors from patients with distant metastases (M1) displayed significantly increased expression of STAT1 and STAT3 but decreased expression of STAT4 and STAT5. Increased tumor expression of STAT1 or STAT3 was associated with impaired patient survival, whereas increased expression of STAT4 or STAT5 correlated with improved survival. Multivariate analysis identified an increased STAT3/STAT5 expressional ratio as an adverse prognostic marker in colon cancer patients.
CONCLUSIONS: The tumor progression-associated transcription factors STAT3, STAT4, and STAT5 are differently expressed in colon carcinoma tissue and colon mucosa. Moreover, the STAT3/STAT5 expression ratio is an independent prognostic marker in colon cancer patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25773877     DOI: 10.1245/s10434-015-4485-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

1.  Novel Proteome Extraction Method Illustrates a Conserved Immunological Signature of MSI-H Colorectal Tumors.

Authors:  Elez D Vainer; Juliane Kania-Almog; Ghadeer Zatara; Yishai Levin; Gilad W Vainer
Journal:  Mol Cell Proteomics       Date:  2020-07-08       Impact factor: 5.911

2.  Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.

Authors:  Satoshi Matsusaka; Diana L Hanna; Shu Cao; Wu Zhang; Dongyun Yang; Yan Ning; Yu Sunakawa; Satoshi Okazaki; Martin D Berger; Yuji Miyamato; Anish Parekh; Sebastian Stintzing; Fotios Loupakis; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2016-02-02       Impact factor: 12.531

3.  Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.

Authors:  David Fogelman; Antonio Cubillo; Pilar García-Alfonso; María Luisa Limón Mirón; John Nemunaitis; Daniel Flora; Christophe Borg; Laurent Mineur; Jose M Vieitez; Allen Cohn; Gene Saylors; Albert Assad; Julie Switzky; Li Zhou; Johanna Bendell
Journal:  Cancer Med       Date:  2018-08-19       Impact factor: 4.452

Review 4.  STAT3 and STAT5 Activation in Solid Cancers.

Authors:  Sebastian Igelmann; Heidi A Neubauer; Gerardo Ferbeyre
Journal:  Cancers (Basel)       Date:  2019-09-25       Impact factor: 6.639

Review 5.  Balancing STAT Activity as a Therapeutic Strategy.

Authors:  Kelsey L Polak; Noah M Chernosky; Jacob M Smigiel; Ilaria Tamagno; Mark W Jackson
Journal:  Cancers (Basel)       Date:  2019-11-03       Impact factor: 6.575

6.  LINC00858 promotes colon cancer progression through activation of STAT3/5 signaling by recruiting transcription factor RAD21 to upregulate PCNP.

Authors:  Ting Xu; Kun Wu; Jin Shi; Lindong Ji; Xudong Song; Guoquan Tao; Shutao Zheng; Li Zhang; Baofei Jiang
Journal:  Cell Death Discov       Date:  2022-04-25

Review 7.  The Interaction Between Autophagy and JAK/STAT3 Signaling Pathway in Tumors.

Authors:  Jiangyan Xu; Jinrong Zhang; Qi-Fen Mao; Jian Wu; Yuan Wang
Journal:  Front Genet       Date:  2022-04-26       Impact factor: 4.772

Review 8.  Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer.

Authors:  Sebastian Zundler; Markus F Neurath
Journal:  Vaccines (Basel)       Date:  2016-02-29

9.  A 65‑gene signature for prognostic prediction in colon adenocarcinoma.

Authors:  Hui Jiang; Jun Du; Jiming Gu; Liugen Jin; Yong Pu; Bojian Fei
Journal:  Int J Mol Med       Date:  2018-01-18       Impact factor: 4.101

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.